Archives
-
TG003 and CLK2: What the Evidence Shows
2026-10-11
The supplied ovarian-cancer study supports a model in which CLK2 is associated with platinum resistance through BRCA1 phosphorylation and DNA-damage repair in experimental models. It does not, however, establish that TG003 was used, that TG003 selectively inhibits CLK2 in cells, or that the compound improves patient outcomes. APExBIO describes TG003 as a multi-target Cdc2-like kinase inhibitor whose relevance to alternative splicing research must be separated from evidence for cancer treatment.
-
TSPAN18, STIM1, and Calcium Signaling in Prostate Cancer
2026-10-10
Zhou et al. identify TSPAN18 as a regulator of STIM1 stability, showing that it can shield STIM1 from TRIM32-mediated ubiquitination and degradation. The study links this molecular interaction to sustained store-operated calcium entry, prostate cancer migration and invasion, and bone metastasis, while also defining important limits for translating calcium perturbation into therapeutic conclusions.
-
Nanoplastic–Cadmium Apoptosis via IP3R/Ca2+/STAT3
2026-10-09
A 2026 Toxicology study connects polystyrene nanoplastic and cadmium co-exposure with intestinal apoptosis in both C. elegans and Caco-2 cells. Its central contribution is mechanistic evidence that IP3R-associated calcium signaling and downstream STAT3 activation participate in the response, although the findings remain bounded by model, exposure, and pharmacological-specificity limitations.
-
CLK2, BRCA1, and Platinum Resistance in Ovarian Cancer
2026-10-09
A 2024 study identifies CLK2 as a potential determinant of platinum resistance in ovarian cancer and links its activity to BRCA1 phosphorylation at Ser1423 and DNA damage repair. The findings provide a mechanistic basis for studying CLK2-directed interventions, while remaining preclinical and model-dependent.
-
Monomeric Aβ and Microglial Control of Brain Development
2026-10-08
Kwon et al. identify a monomeric amyloid-β signaling pathway involving APP and Ric8a in microglia, linking Aβ biology to immune regulation and neocortical development. The findings broaden interpretation of Aβ beyond aggregate-associated toxicity, while the study’s mouse and in vitro evidence does not establish a direct causal role for monomer depletion in human Alzheimer’s disease.
-
HMGCS2, LysoPC, and Pulmonary Fibrosis
2026-10-08
Yang et al. identify injured type II alveolar epithelial cells as a major source of accumulated lysophosphatidylcholines in experimental pulmonary fibrosis and connect this lipid shift to fibroblast activation. The study further defines an HMGCS2–PPARα–CPT1A/CPT2 relationship that links epithelial lipid handling with fibrotic progression, while also highlighting important boundaries between experimental evidence and clinical application.
-
Amyloid Beta-Peptide (1-40): Calcium & Membranes
2026-10-07
Amyloid Beta-Peptide (1-40) (human) is examined here as a membrane-interface model rather than only an amyloid plaque surrogate. The article interprets recent calcium-dependent aggregation evidence, clarifies what the measurements can and cannot establish, and explains the research value of Aβ40.
-
FPS-ZM1 and RAGE Signaling: Evidence Review
2026-10-07
FPS-ZM1 is a research-stage RAGE inhibitor used to study amyloid beta (Aβ) signaling, neuroinflammation, and blood-brain barrier transport. A 2026 pre-proof study extends RAGE biology into hypothalamic POMC and metabolic regulation, but it does not establish that FPS-ZM1 reproduces berberine’s effects or support clinical use.
-
HABA and the Next Layer of PLGA Translation
2026-10-06
PLGA microspheres for intra-articular delivery are often evaluated through size, surface charge, transport, and release. The 2026 Pharmaceutics study by Samonte and Comolli shows why those measurements should be interpreted together: apparent diffusion can reflect steric restriction, while surface chemistry can influence corticosteroid stability. This thought-leadership article examines how HABA (4′-Hydroxyazobenzene-2-carboxylic acid) could add a functional layer to avidin–biotin characterization by assessing accessible binding sites, while clearly separating conceptual opportunity from findings reported in the anchor study.
-
From ROS Suppression to Translational Strategy
2026-10-06
A mechanistic analysis of how TaCRVP reshapes tomato redox defense, and how fluorescent RNA labeling can support better evidence architecture in translational plant research.
-
Doxycycline Hyclate as a Mechanistic Probe
2026-10-05
Doxycycline hyclate is more than a broad-spectrum antibiotic in research: it can function as a matrix metalloproteinases inhibitor for testing MMP-linked vascular and neuroinflammatory mechanisms. This article interprets evidence from a 2024 mouse study while distinguishing mechanistic insight from causal certainty and cross-domain extrapolation.
-
NLRP10, Keratinocyte Survival, and Epidermal Barrier
2026-10-05
The 2024 Cell Death and Disease study positions NLRP10 as an epidermal homeostasis factor that links keratinocyte survival with p63-dependent differentiation and barrier function. By combining evidence from atopic dermatitis skin and an air-lift human skin equivalent model, the authors move NLRP10 from genetic association toward a mechanistic disease framework while recognizing that therapeutic translation remains untested.
-
FPS-ZM1 and RAGE Signaling: Evidence and Limits
2026-10-04
FPS-ZM1 is a research-stage RAGE inhibitor proposed for studying amyloid beta signaling, neuroinflammation, and related receptor biology. A 2026 pre-proof study linked berberine, RAGE, and hypothalamic POMC signaling to metabolic outcomes in cells and mice, but it did not test FPS-ZM1. This overview compares the evidence, clarifies what the findings do and do not establish, and outlines limitations affecting Alzheimer’s disease research and metabolic applications.
-
Amyloid β-Peptide (1-42): Research Evidence
2026-10-03
Amyloid β-Peptide (1-42), or Aβ42 peptide, is widely studied in Alzheimer’s disease research because its aggregation, neuronal effects, and interactions with cellular systems may illuminate disease mechanisms. This overview evaluates a 2024 ratiometric fluorescence study, separates direct findings from interpretation, and defines the limits of translating in vitro fibril detection into biological or clinical conclusions.
-
Chronic Cabozantinib Remodeling in RCC
2026-10-02
This study uses quantitative phosphoproteomics to distinguish acute from chronic Cabozantinib adaptation in renal cell carcinoma cells. It identifies sustained MET activation-loop suppression alongside selective adhesion, stress, and MAPK/AP-1-associated remodeling, with modest and pattern-specific changes in migration and invasion.